Volker Braun - Evotec SE Executive ESG
| EVO Stock | USD 4.49 0.86 16.07% |
Executive
Volker Braun is Executive ESG of Evotec SE ADR
| Address | Essener Bogen 7, Hamburg, Germany, 22419 |
| Phone | 49 40 560 81 0 |
| Web | https://www.evotec.com |
Evotec SE Management Efficiency
The company has Return on Asset of (0.0177) % which means that on every $100 spent on assets, it lost $0.0177. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.1625) %, meaning that it generated no profit with money invested by stockholders. Evotec SE's management efficiency ratios could be used to measure how well Evotec SE manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of November 2024, Return On Tangible Assets is likely to drop to -0.04. In addition to that, Return On Capital Employed is likely to drop to -0.03. At this time, Evotec SE's Intangibles To Total Assets are very stable compared to the past year. As of the 25th of November 2024, Debt To Assets is likely to grow to 0.20, while Other Assets are likely to drop 1.09.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Michael Hassman | Scpharmaceuticals | N/A | |
| Rachael Nokes | Scpharmaceuticals | 49 | |
| Lee Flowers | HCW Biologics | 78 | |
| Nicole Esq | HCW Biologics | N/A | |
| Carlo Tanzi | Seres Therapeutics | N/A | |
| David Ege | Seres Therapeutics | 49 | |
| JD Esq | Seres Therapeutics | 69 | |
| Eddie MBA | Lumos Pharma | N/A | |
| Nishi MD | Eliem Therapeutics | N/A | |
| Jeffrey Nelson | Milestone Pharmaceuticals | 43 | |
| Alpa Parikh | Lumos Pharma | N/A | |
| Valerie Morisset | Eliem Therapeutics | 54 | |
| SPHR SHRMSCP | Seres Therapeutics | 52 | |
| Lisa MD | Seres Therapeutics | 65 | |
| MD FAAP | Lumos Pharma | N/A | |
| Caroline Holda | Seres Therapeutics | N/A | |
| MD MBA | Eliem Therapeutics | 50 | |
| John PharmD | Scpharmaceuticals | N/A | |
| Kim Fox | Milestone Pharmaceuticals | N/A | |
| Matthew Henn | Seres Therapeutics | 49 | |
| Roshan Girglani | Milestone Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.16 | ||||
| Return On Asset | -0.0177 |
Evotec SE ADR Leadership Team
Elected by the shareholders, the Evotec SE's board of directors comprises two types of representatives: Evotec SE inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Evotec. The board's role is to monitor Evotec SE's management team and ensure that shareholders' interests are well served. Evotec SE's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Evotec SE's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Matthias Evers, Chief Board | ||
| Mario DPHIL, Member CEO | ||
| Monika Conradt, Global Resources | ||
| MBA MPA, Member Board | ||
| Christian Dargel, EVP Compliance | ||
| Anja Bosler, Principal Accounting | ||
| David Hallet, Executive President | ||
| Volker Braun, Executive ESG | ||
| Christian Wojczewski, Chief Officer | ||
| Cord Dohrmann, Chief Board | ||
| Ian Hunneyball, Senior Operations | ||
| Enno Spillner, CFO Board | ||
| MBA MBA, Chairman CEO | ||
| Gabriele Hansen, Senior Marketing | ||
| Aurelie Dalbiez, Chief Board | ||
| Craig Johnstone, COO Board | ||
| Laetitia Rouxel, CFO Board |
Evotec Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Evotec SE a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.16 | ||||
| Return On Asset | -0.0177 | ||||
| Profit Margin | (0.22) % | ||||
| Operating Margin | (0.18) % | ||||
| Current Valuation | 1.68 B | ||||
| Shares Outstanding | 355.11 M | ||||
| Shares Owned By Institutions | 2.19 % | ||||
| Number Of Shares Shorted | 220.13 K | ||||
| Price To Earning | 444.00 X | ||||
| Price To Book | 1.57 X |
Pair Trading with Evotec SE
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evotec SE position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evotec SE will appreciate offsetting losses from the drop in the long position's value.Moving against Evotec Stock
| 0.9 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.84 | TCHH | Trustcash Holdings | PairCorr |
| 0.77 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
| 0.75 | AGL | agilon health | PairCorr |
| 0.74 | ME | 23Andme Holding | PairCorr |
The ability to find closely correlated positions to Evotec SE could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evotec SE when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evotec SE - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evotec SE ADR to buy it.
The correlation of Evotec SE is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evotec SE moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evotec SE ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Evotec SE can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evotec SE ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evotec SE. If investors know Evotec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evotec SE listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.52) | Revenue Per Share 2.1925 | Quarterly Revenue Growth (0.06) | Return On Assets (0.02) | Return On Equity (0.16) |
The market value of Evotec SE ADR is measured differently than its book value, which is the value of Evotec that is recorded on the company's balance sheet. Investors also form their own opinion of Evotec SE's value that differs from its market value or its book value, called intrinsic value, which is Evotec SE's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evotec SE's market value can be influenced by many factors that don't directly affect Evotec SE's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evotec SE's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evotec SE is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evotec SE's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.